Haybury

Haybury

57 Follower

11-50 Mitarbeitende

Neuigkeiten

Alle Neuigkeiten

Hayburyhat einen Beitrag geschrieben.28. Februar 2019

Immatics, Roche ally to trial Tecentriq with cell therapy https://bit.ly/2U9zMMj

Immatics, Roche ally to trial Tecentriq with cell therapy

Immatics has struck a deal to test its autolog | Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors.www.fiercebiotech.com

Hayburyhat einen Beitrag geschrieben.28. Februar 2019

Syncona, Novartis back IL-2 immuno-oncology startup Anaveon https://bit.ly/2BWX8hd

Syncona, Novartis back IL-2 immuno-oncology startup Anaveon

Syncona and Novartis have invested in Anaveon. | Syncona and Novartis have invested in Anaveon. The $35 million series A round sets Anaveon up to advance a preclinical asset designed to enhance anti-tumor immune responses. www.fiercebiotech.com

Hayburyhat einen Beitrag geschrieben.27. Februar 2019

Boehringer Ingelheim appoints new chief medical officer https://bit.ly/2VsNQRB

Boehringer Ingelheim appoints new chief medical officer - PharmaTimes

Boehringer Ingelheim has announced the appointment of Dr Mehdi Shahid as chief medical officer.pharmatimes.com

Hayburyhat einen Beitrag geschrieben.27. Februar 2019

Novartis pays $150M to license Akcea-Ionis cardiac disease drug https://bit.ly/2IFoSg0

Novartis pays $150M to license Akcea-Ionis cardiac disease drug

Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. | Novartis has taken up its option to license antisense oligonucleotide TQJ230, triggering a $150 million payout that Akcea Therapeutics will share with Ionis Pharmaceuticals. The decision sets Novartis up to test the RNA-targeting drug in a phase 3 cardiovascular outcomes trial.www.fiercebiotech.com

Hayburyhat einen Beitrag geschrieben.25. Februar 2019

Ipsen acquires Clementia in bid to boost rare disease portfolio https://bit.ly/2SryZVo

Ipsen acquires Clementia in bid to boost rare disease portfolio - PharmaTimes

Ipsen has announced plans to acquire Clementia Pharmaceuticals.pharmatimes.com

Hayburyhat einen Beitrag geschrieben.20. Februar 2019

First patient dosed in Gyroscope Therapeutics’ AMD study https://bit.ly/2GzztaF

First patient dosed in Gyroscope Therapeutics’ AMD study - PharmaTimes

Gyroscope Therapeutics has announced that the first patient has been dosed in its Phase I/II FOCUS study for dry age-related macular degeneration (AMD).pharmatimes.com

Hayburyhat einen Beitrag geschrieben.20. Februar 2019

Novartis’ AveXis doubles down with $115M manufacturing investment https://bit.ly/2Sc8bZl

Novartis’ AveXis doubles down with $115M manufacturing investment

As an FDA action date quickly approaches for a gene therapy that Novartis snatched up last year, the biotech that is developing the treatment says it needs to more than double the size of | AveXis, which Novartis acquired last year for $8.7 billion, announced it will invest another $60 million and hire another 200 workers for the site it is building in Durham, North Carolina. That is on top of the $55 million it pledged to invest in the plant last year when it first projected hiring 200 employees.www.fiercepharma.com

Hayburyhat einen Beitrag geschrieben.18. Februar 2019

Johnson & Johnson, Takeda and Evotec join The Dementia Consortium https://bit.ly/2S2QRFN

Johnson & Johnson, Takeda and Evotec join The Dementia Consortium - PharmaTimes

The Dementia Consortium has expanded to include Johnson & Johnson Innovation, Takeda and Evotec, who join the unique £9.5 million charity-industry dementia drug discovery collaboration.pharmatimes.com

Hayburyhat einen Beitrag geschrieben.18. Februar 2019

Could AI predict survival of ovarian cancer patients? https://bit.ly/2SStUcX

Could AI predict survival of ovarian cancer patients? - PharmaTimes

Researchers have created new AI machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.pharmatimes.com

Hayburyhat einen Beitrag geschrieben.6. Februar 2019

Merck’s Prevnar challenger nabs FDA ‘breakthrough’ tag. Should Pfizer be worried? https://bit.ly/2GlRng6

Merck’s Prevnar challenger nabs FDA ‘breakthrough’ tag. Should Pfizer be worried?

Merck & Co.’s endeavor to challenge Prevnar 13, the world’s best-selling vaccine, just got a speed-up. But it doesn’t appear to have too much of a lead over rival Pfizer. | Merck & Co.’s endeavor to challenge Prevnar 13, the world’s best-selling vaccine, just got a speed-up. But except for a small head start in phase 3 trials, the blockbuster's would-be rival doesn’t appear to have a big lead over Pfizer, which is developing a 20-strain shot.www.fiercepharma.com

Alle Neuigkeiten

XING empfiehlt folgende Unternehmen:

LEANTECHNIK AG

WEMA VOGTLAND Technology GmbH

Metallbau Lührmann

Über uns

Alle Infos ansehen

Haybury are an Executive Search Consultancy who are committed to providing solutions and creating opportunities through innovation and collaboration. We focus solely within Life Sciences, working to place key people in key positions across leading pharmaceutical and biotech companies, CROs and start-ups. Our roles are...

Alle Infos ansehen